Back to Search
Start Over
Evaluation of the Revogene® GBS DS assay performance for the intrapartum screening of group B streptococcus in comparison with intrapartum culture.
- Source :
-
Diagnostic Microbiology & Infectious Disease . Mar2022, Vol. 102 Issue 3, pN.PAG-N.PAG. 1p. - Publication Year :
- 2022
-
Abstract
- Prevention of perinatal Group B Streptococcus (GBS) transmission is crucial in our effort to prevent Early-onset GBS disease. Here, we established the performance of the Revogene GBS DS assay for the detection of group B streptococcus on intrapartum vaginal samples in a laboratory environment using a prospective noninterventional study design. Intrapartum vaginal swabs were enriched using a selective culture method which served as study reference method. Overall, 119 patients were enrolled with an antenatal and intrapartum Group B Streptococcus colonization prevalence of 12.9% and 11.8%, respectively. Compared to intrapartum culture, the Revogene GBS DS assay had a sensitivity of 92.9% and a specificity of 99.1%, while the antenatal culture displayed a sensitivity 78.6% of and specificity of 96.2%. The Revogene GBS DS assay displayed an acceptable performance according to the European Group B Streptococcus consensus recommendations. Complementary studies in clinical practice are needed to confirm these findings. [ABSTRACT FROM AUTHOR]
- Subjects :
- *STREPTOCOCCUS agalactiae
*CROSS-cultural studies
*MEDICAL screening
Subjects
Details
- Language :
- English
- ISSN :
- 07328893
- Volume :
- 102
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Diagnostic Microbiology & Infectious Disease
- Publication Type :
- Academic Journal
- Accession number :
- 155122045
- Full Text :
- https://doi.org/10.1016/j.diagmicrobio.2021.115616